| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| DEFA14A | Additional proxy soliciting materials - definitive |
Proxy Filings
|
||
| PREM14A | A preliminary proxy statement relating to a merger or acquisition |
Mergers & Acquisitions
|
||
| DEFA14A | Additional proxy soliciting materials - definitive |
Proxy Filings
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| DEFA14A | Additional proxy soliciting materials - definitive |
Proxy Filings
|
||
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
||
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
||
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
||
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
